Fractyl Health Inc., a company specializing in metabolic therapeutics, has announced that it will present new preclinical data from its Rejuva® Smart GLP-1™ pancreatic gene therapy platform. The presentation is scheduled to take place at the American Diabetes Association's 85th Scientific Sessions in Chicago, Illinois, from June 20-23, 2025. The data will be shared in a poster session titled "Single-Dose GLP-1-Based Pancreatic Gene Therapy Prevents Obesity and Diabetes in High-Fat-Fed Mice." The presentation is set for June 22, 2025, from 12:30 p.m. to 1:30 p.m. The poster will be available on the Fractyl website following the session.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.